https://www.selleckchem.com/pr....oducts/hc-030031.htm
65, 95% confidence interval (CI) 0.50-0.85, p = 0.002), higher NRM (HR = 1.60, 95% CI 1.10-2.33, p = 0.013) and better leukemia-free survival (HR = 0.77, 95% CI 0.63-0.95, p = 0.015) compared with FBiv. These results suggest that Flu + Mel has a more intense disease control potential and Flu + ivBu is less toxic than the other. Both RIC regimens provide similar survival outcomes and are effective and useful regimens for patients with AML who received allo-HCT.BRCA1/2 genetic testing to use PARP inhibitor for breast cancer has a possib
Like
Comment
Share
